CN111971027A - 副甲状腺素类似物的口服制剂及治疗 - Google Patents

副甲状腺素类似物的口服制剂及治疗 Download PDF

Info

Publication number
CN111971027A
CN111971027A CN202080001216.3A CN202080001216A CN111971027A CN 111971027 A CN111971027 A CN 111971027A CN 202080001216 A CN202080001216 A CN 202080001216A CN 111971027 A CN111971027 A CN 111971027A
Authority
CN
China
Prior art keywords
pharmaceutical composition
containing compound
oral pharmaceutical
metal
chromium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080001216.3A
Other languages
English (en)
Chinese (zh)
Inventor
史格瑞·葛林瑟
布尚·德鲁库码·迪赛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omenya Co ltd
Original Assignee
Omenya Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omenya Co ltd filed Critical Omenya Co ltd
Publication of CN111971027A publication Critical patent/CN111971027A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080001216.3A 2019-03-08 2020-03-06 副甲状腺素类似物的口服制剂及治疗 Pending CN111971027A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921009082 2019-03-08
IN201921009082 2019-03-08
PCT/IB2020/051958 WO2020183318A1 (en) 2019-03-08 2020-03-06 Oral formulation and treatment of pth analog.

Publications (1)

Publication Number Publication Date
CN111971027A true CN111971027A (zh) 2020-11-20

Family

ID=72426161

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080001216.3A Pending CN111971027A (zh) 2019-03-08 2020-03-06 副甲状腺素类似物的口服制剂及治疗

Country Status (6)

Country Link
US (1) US20220133857A1 (https=)
JP (2) JP7610410B2 (https=)
KR (1) KR20210137373A (https=)
CN (1) CN111971027A (https=)
TW (1) TWI821541B (https=)
WO (1) WO2020183318A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210137373A (ko) * 2019-03-08 2021-11-17 안야 바이오팜 인코포레이티드 부갑상샘 호르몬 유사체의 경구 제제 및 치료
EP4226918A1 (en) * 2022-02-15 2023-08-16 Filip Majewski Pharmaceutical single dosage form for oral delivery of peptides
KR102844771B1 (ko) * 2022-07-22 2025-08-12 주식회사 아이큐어비앤피 테리파라타이드를 포함하는 골다공증 예방 또는 치료를 위한 경구용 약학적 조성물 및 이의 제조방법
WO2025037993A1 (en) 2023-08-13 2025-02-20 Filip Majewski Dosage form for peptide agents

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121025A1 (en) * 2002-12-20 2004-06-24 Mckee Dwight Oral composition for the treatment and prevention of bone loss
US20110059892A1 (en) * 2004-06-14 2011-03-10 Philippe Moussou Cosmetic preparations containing PTH fragments
US20140378382A1 (en) * 2013-06-23 2014-12-25 Massachusetts General Hospital Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same
RU2013130611A (ru) * 2008-08-18 2015-01-10 Интера Био Лтд. Способы и композиции для перорального введения белков
US20170304195A1 (en) * 2014-10-07 2017-10-26 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide or protein drugs
CN108135962A (zh) * 2015-10-07 2018-06-08 塞浦路迈德有限责任公司 用于口服递送肽类药物的药物制剂
US20200121796A1 (en) * 2017-09-21 2020-04-23 Anya Biopharm Inc. Pharmaceutical compositions for delivery of peptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1228708A (zh) * 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
US6946151B2 (en) * 2002-11-12 2005-09-20 Ayurvedic-Life International, Llc Therapeutic compositions
CN1816324A (zh) * 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
US20180036382A1 (en) * 2015-02-09 2018-02-08 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
KR20210137373A (ko) * 2019-03-08 2021-11-17 안야 바이오팜 인코포레이티드 부갑상샘 호르몬 유사체의 경구 제제 및 치료

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040121025A1 (en) * 2002-12-20 2004-06-24 Mckee Dwight Oral composition for the treatment and prevention of bone loss
US20110059892A1 (en) * 2004-06-14 2011-03-10 Philippe Moussou Cosmetic preparations containing PTH fragments
RU2013130611A (ru) * 2008-08-18 2015-01-10 Интера Био Лтд. Способы и композиции для перорального введения белков
US20140378382A1 (en) * 2013-06-23 2014-12-25 Massachusetts General Hospital Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same
US20170304195A1 (en) * 2014-10-07 2017-10-26 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide or protein drugs
CN108135962A (zh) * 2015-10-07 2018-06-08 塞浦路迈德有限责任公司 用于口服递送肽类药物的药物制剂
US20180280481A1 (en) * 2015-10-07 2018-10-04 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
US20200121796A1 (en) * 2017-09-21 2020-04-23 Anya Biopharm Inc. Pharmaceutical compositions for delivery of peptide

Also Published As

Publication number Publication date
JP7610410B2 (ja) 2025-01-08
TWI821541B (zh) 2023-11-11
TW202100182A (zh) 2021-01-01
US20220133857A1 (en) 2022-05-05
JP2024178360A (ja) 2024-12-24
KR20210137373A (ko) 2021-11-17
JP2022522550A (ja) 2022-04-20
WO2020183318A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
TWI821541B (zh) Pth類似物之口服製劑及治療
KR100498646B1 (ko) 경구용 펩티드 약학적 조성물
ES2929218T3 (es) Formas farmacéuticas orales sólidas
JP2018529749A5 (https=)
US12208118B2 (en) Pharmaceutical compositions for delivery of peptide
US20110311621A1 (en) Pharmaceutical compositions and methods of delvery
US20250000933A1 (en) Terlipressin compositions and their methods of use
US20240041983A1 (en) Improved pharmaceutical formulations of glp-1 receptor agonists
JP2011502144A (ja) ヴァンコマイシンのための経口吸収固体投与調剤
CN1809377B (zh) 包含微粉化形式的传送剂的口服给药药物组合物
EP2964193B1 (en) Pharmaceuticals for oral delivery
JP5892940B2 (ja) クラウン化合物及び／又は対イオンと複合体化されたペプチドを含む粘膜送達組成物
EP4026566B1 (en) Oral pharmaceutical composition comprising teriparatide and method for preparing same
WO2020237170A1 (en) Formulations of terlipressin
BR112018016545B1 (pt) Formulação farmacêutica liofilizada e seu uso
CN101039698B (zh) 稳定的白三烯b4(ltb4)药剂的药学配方
US20080207745A1 (en) Orally-absorbed formulation for paromomycin
US20240108578A1 (en) Composition in which absorbability of poorly absorbable drug is improved
HK40014065B (en) Terlipressin composition for use in treating ascites
HK40014065A (en) Terlipressin composition for use in treating ascites
WO2008103148A1 (en) An orally-absorbed formulation for paromomycin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination